Salt Selection in Drug Development - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Salt Selection in Drug Development
The selection of an appropriate salt form for a potential drug candidate is an opportunity to modulate its characteristics to improve bioavailability, stability, manufacturability, and patient compliance.


Pharmaceutical Technology
Volume 3, Issue 32

Generation of salt forms. Salts can be prepared on a small scale using various methods. Forming salts from free acid or base is the most common method. The free acid or base of the drug substance is combined with the counterion base or acid in specific molar ratios in a suitable solvent system. The salt form is then isolated, and the solid precipitate is recrystallized. A less common method is to form salts through salt exchange. In this method, a counterion salt is treated with a free acid or base in a specific molar concentration in a suitable solvent. The solid is then isolated and recrystallized. The sulfate salt of methyl pyridinium-2-aldoxime was prepared using silver sulfate as a counterion. The unwanted silver ions were removed as insoluble iodide salt, and the desired sulfate salt was precipitated by adding antisolvent (36). A wide range of salts are generally prepared for each new substance. Their properties are compared during a preformulation program that improves the chances of selecting the optimal salt form (29). However, a balanced approach should be adopted because limited resources are available at this early stage of drug development. Commonly used salts such as hydrochlorides and sodium have advantages over other salt-forming moieties. For example, they have low molecular weight and low toxicity. However, other salt forms such as mesylate may sometimes offer advantages such as higher solubility and bioavailability (37).


Figure 2: The pH-solubility profile for a compound with a single, basic pKa value of 5. The four regions of pH-dependent solubility are: salt plateau, pHmax, ionized compound, and unionized compound.
High-throughput synthesis has gained greater importance in the salt-selection process. This technique allows many counterions and crystallization solvents to be evaluated using as little as 50 mg of drug substance. After the optimum drug-substance form is selected at the microlevel, the synthesis of the compound can be scaled up to several hundred grams to test for other stages of preformulation (27). In situ salt screening also offers a viable alternative to traditional salt screening (34). This method has a special relevance for poorly soluble compounds because it can rapidly rank compounds based on their solubility, effectively screening out insoluble compounds immediately (13). During in situ salt screening, a known concentration of drug is added to a concentrated counterion solution sufficient to obtain the pHmax (see Figure 2) for successful salt formation that may be subjected to solubility screening. Tong applied in situ salt screening to GW1818, an alpha 1A adrenergic receptor antagonist, and short-listed four salts—the phosphate, succinate, mesylate, and hydrochloride—for further development. These salts were found to be crystalline with adequate solubility (comparable with the authentic salts later prepared by the traditional method) and were selected for further evaluation (34).


Table III: Salt forms in USP 2006.
In spite of the abundance of available counterions, few are used frequently. The preference for pharmaceutical counter-ions is explained by studying the distribution of different counterions of medicinal compounds in USP 2006 (38) (see Table III). The table shows that salt forms of drugs (56.15%) are preferred over free forms (43.85%). Hydrochloride and sodium remain the favorite counterions for the salt formation of medicinal compounds. However, the availability of many pharmaceutically acceptable counterions makes the salt-selection process difficult and cumbersome.

Salt-form selection. The generated salt forms are compared for the desired physico-chemical and biopharmaceutical properties, which guide the final selection of an optimal salt form.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
42%
No government involvement in patient treatment or drug development.
12%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here